Ovid Therapeutics (OVID) closed at $2.45 on October 28, 2026, up 8.4% from the previous close, on volume of 1,953,073 shares (30-day average 1,822,454).
Data as of October 28, 2026.
28-Oct-2026
PRNewswire (Thu, 15-Oct 7:30 AM ET)
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 3-Sep 8:00 AM ET)
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Globe Newswire (Thu, 13-Aug 8:30 AM ET)
Ovid Therapeutics Secures $60 Million to Advance OV329 in Tuberous Sclerosis and Infantile Spasms
Market Chameleon (Wed, 18-Mar 6:30 AM ET)
Market Chameleon (Fri, 3-Oct 6:39 AM ET)
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Ovid Therapeutics trades on the NASDAQ stock market under the symbol OVID.
As of October 28, 2026, OVID stock price climbed to $2.45 with 1,953,073 million shares trading.
OVID has a beta of 1.64, meaning it tends to be more sensitive to market movements. OVID has a correlation of 0.07 to the broad based SPY ETF.
OVID has a market cap of $478.48 million. This is considered a Small Cap stock.
Last quarter Ovid Therapeutics reported $733,000 in Revenue and -$.08 earnings per share. This beat revenue expectation by $703,000 and exceeded earnings estimates by $.02.
In the last 3 years, OVID traded as high as $4.10 and as low as $.24.
The top ETF exchange traded funds that OVID belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
OVID has outperformed the market in the last year with a price return of +53.1% while the SPY ETF gained +13.8%. However, in the short term, OVID had mixed performance relative to the market. It has underperformed in the last 3 months, returning +4.3% vs +4.8% return in SPY. But in the last 2 weeks, OVID shares have fared better than the market returning +11.9% compared to SPY -0.7%.
OVID support price is $2.16 and resistance is $2.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OVID shares will trade within this expected range on the day.
